- cafead Mar 07, 2022 at 10:32: AM
via Eli Lilly and Boehringer Ingelheim’s diabetes blockbuster Jardiance recently snagged a heart failure label expansion in the U.S. Now, the drug is widening its cardiovascular reach into Europe, with a nod that could help the med play catch-up with AstraZeneca’s SGLT2 rival Farxiga.
article source
article source